Lv2
130 积分 2024-07-25 加入
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
5小时前
已完结
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
1个月前
已关闭
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
2个月前
已完结
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
2个月前
已完结
Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents A Phase 3 Randomized Clinical Trial
5个月前
已关闭
Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents A Phase 3 Randomized Clinical Trial
5个月前
已完结
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
6个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
6个月前
已完结
The design and discovery of phospholipase A2 inhibitors for the treatment of inflammatory diseases
6个月前
已完结
GSK's darapladib failures dim hopes for anti-inflammatory heart drugs
6个月前
已完结
皖公网安备34019202002308
